Renhe Pharmaceutical announced that as of August 5, 2026, the company has completed share repurchases. This time, a total of 17.705 million shares were repurchased through centralized bidding transactions, accounting for 1.2643% of the company's total share capital. The total transaction amount was 99.996 million yuan, and the repurchase price was 4.86 yuan/share - 5.73 yuan/share. This repurchase complies with relevant regulations and will not have a significant impact on the company's operations, profitability, etc. Shares are to be repurchased for employee shareholding or equity incentive plans, and will be cancelled if not approved or granted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.